AU6426898A - An enteric coated oral dosage form comprising sodium amoxycillin - Google Patents

An enteric coated oral dosage form comprising sodium amoxycillin

Info

Publication number
AU6426898A
AU6426898A AU64268/98A AU6426898A AU6426898A AU 6426898 A AU6426898 A AU 6426898A AU 64268/98 A AU64268/98 A AU 64268/98A AU 6426898 A AU6426898 A AU 6426898A AU 6426898 A AU6426898 A AU 6426898A
Authority
AU
Australia
Prior art keywords
dosage form
oral dosage
enteric coated
coated oral
sodium amoxycillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64268/98A
Inventor
Stig Wendsjo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of AU6426898A publication Critical patent/AU6426898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU64268/98A 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin Abandoned AU6426898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9700885 1997-03-12
SE9700885A SE9700885D0 (en) 1997-03-12 1997-03-12 New pharmaceutical formulation
PCT/SE1998/000356 WO1998040054A1 (en) 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin

Publications (1)

Publication Number Publication Date
AU6426898A true AU6426898A (en) 1998-09-29

Family

ID=20406120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64268/98A Abandoned AU6426898A (en) 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin

Country Status (5)

Country Link
EP (1) EP0981335A1 (en)
JP (1) JP2001515489A (en)
AU (1) AU6426898A (en)
SE (1) SE9700885D0 (en)
WO (1) WO1998040054A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862431B1 (en) 1995-09-07 2001-11-14 Smithkline Beecham Corporation Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
AR031068A1 (en) * 1999-04-13 2003-09-10 Beecham Pharm Pte Ltd A PHARMACEUTICAL FORMULATION OF MODIFIED RELEASE THAT INCLUDES AMOXICILLIN AND POTASSIUM CLAVULANATE IN A RATIO OF 2: 1 TO 20: 1, A COMPRESSED IN LAYERS, THE USE OF AMOXYCLINE AND THE POTASSIUM CLAVULANATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT COMPACT GRANULES
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
SE0101379D0 (en) * 2001-04-18 2001-04-18 Diabact Ab Composition that inhibits gastric acid secretion
ES2198195B1 (en) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. COMPRESSED ORAL PHARMACEUTICAL DOSAGE FORM, WITH ENTERIC COATING, CONTAINING A LABIL BENCIMIDAZOL COMPOUND IN THE MIDDLE ACID.
SE0203065D0 (en) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2006132127A (en) * 2006-09-06 2008-03-20 Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru) APPLICATION OF NIFUROXASIDE AS A COMPONENT OF COMBINED MEDICINE THERAPY OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI, AND A METHOD OF TREATMENT AIMED AT ERADICATION OF AN ACTIVATOR
ES2744406T3 (en) 2013-02-13 2020-02-25 Redhill Biopharma Ltd Pharmaceutical compositions for the treatment of helicobacter pylori
WO2016112254A1 (en) * 2015-01-09 2016-07-14 The Regents Of The University Of California Compositions and methods for treating gastrointestinal infections
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201930D0 (en) * 1992-06-24 1992-06-24 Astra Ab GASTRIC ANTIBACTERIAL TREATMENT
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Also Published As

Publication number Publication date
JP2001515489A (en) 2001-09-18
SE9700885D0 (en) 1997-03-12
WO1998040054A1 (en) 1998-09-17
EP0981335A1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
AU6426898A (en) An enteric coated oral dosage form comprising sodium amoxycillin
AU7375598A (en) Stable oral pharmaceutical dosage forms
AU9187598A (en) Oral preparation
AU5428096A (en) Oral 2-methyl-thieno-benzodiazepine formulation
EP0914119A3 (en) Solid oral dosage forms of valsartan
AU7675296A (en) Gum-massaging oral brush
AU2317699A (en) Dental restoratives
AU3977099A (en) Controlled release oral dosage form
AU1271899A (en) Denture brush
AU4050195A (en) Soft gelatin pharmaceutical dosage form
AU2638297A (en) Oral pharmaceutical preparation containing ibandronat
AU2612999A (en) Oral care composition
AU2620197A (en) Multiphase soft gelatin dosage form
AU4143999A (en) Oral composition comprising capsules
AU7964398A (en) Dental formulation
AU1827799A (en) Oral delivery formulation
AU6784598A (en) Medical plug
AU5401796A (en) Solid delivery form for oral use
AU8356198A (en) Dental remedies containing pth
AU5347996A (en) Preparation for oral administration
AU5378599A (en) Oral formulation
AU6092698A (en) Combination preparation for orally administered antibiotics
AU6473699A (en) Aqueous drug formulation for oral application
AU5951798A (en) Oral application of (+)-O-demethyltramadol as a pain- killing drug
AU2447097A (en) Oral coated active drugs